• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease.

作者信息

Lurje Isabella, Tacke Frank

机构信息

Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.

出版信息

Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1034-1037. doi: 10.21037/hbsn-24-568. Epub 2024 Nov 14.

DOI:10.21037/hbsn-24-568
PMID:39669094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11634436/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ab7/11634436/e446bf95e578/hbsn-13-06-1034-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ab7/11634436/f8924a175ded/hbsn-13-06-1034-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ab7/11634436/e446bf95e578/hbsn-13-06-1034-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ab7/11634436/f8924a175ded/hbsn-13-06-1034-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ab7/11634436/e446bf95e578/hbsn-13-06-1034-f2.jpg

相似文献

1
Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease.用于代谢功能障碍相关脂肪性肝炎的雷斯美洛：针对肝脏和心血管疾病
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1034-1037. doi: 10.21037/hbsn-24-568. Epub 2024 Nov 14.
2
Resmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential.Resmetirom用于治疗代谢功能障碍相关脂肪性肝炎（MASH）：当前证据与治疗潜力的全面综述
Cureus. 2024 Nov 29;16(11):e74772. doi: 10.7759/cureus.74772. eCollection 2024 Nov.
3
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
4
Hepatic thyroid hormone receptor-β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis.肝脏甲状腺激素受体-β信号传导：代谢功能障碍相关脂肪性肝炎治疗的机制与最新进展
Diabetes Obes Metab. 2025 Apr;27(4):1635-1647. doi: 10.1111/dom.16117. Epub 2024 Dec 10.
5
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.体重减轻对代谢功能障碍相关脂肪性肝炎和肝纤维化的影响。
Curr Diab Rep. 2025 Feb 18;25(1):23. doi: 10.1007/s11892-025-01579-1.
6
Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).瑞美替隆：首个获美国食品药品监督管理局批准用于治疗非酒精性脂肪性肝炎（NASH）的药物。
Ann Pharmacother. 2025 Feb;59(2):162-173. doi: 10.1177/10600280241259528. Epub 2024 Jun 17.
7
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.非酒精性脂肪性肝病（MASLD）/非酒精性脂肪性肝炎（MASH）：是否有必要进行标记？全面的叙述性综述。
Int J Mol Sci. 2024 Aug 2;25(15):8462. doi: 10.3390/ijms25158462.
8
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。执行摘要。
Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.
9
Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.代谢功能障碍相关脂肪性肝病相关肝肿瘤的病理学与发病机制
Biomedicines. 2023 Oct 12;11(10):2761. doi: 10.3390/biomedicines11102761.
10
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.选择性甲状腺激素受体-β激动剂 Resmetirom 治疗代谢功能障碍相关脂肪性肝病（MASLD）的疗效和安全性：系统评价和荟萃分析。
Sci Rep. 2024 Aug 26;14(1):19790. doi: 10.1038/s41598-024-70242-8.

本文引用的文献

1
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
2
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
3
Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
美国脂肪性肝病（MASLD、MetALD 和 ALD）的流行情况：NHANES 2017-2020。
Clin Gastroenterol Hepatol. 2024 Jun;22(6):1330-1332.e4. doi: 10.1016/j.cgh.2023.11.003. Epub 2023 Nov 8.
4
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.雷美替胺治疗非酒精性脂肪性肝病：一项随机、双盲、安慰剂对照的 3 期临床试验。
Nat Med. 2023 Nov;29(11):2919-2928. doi: 10.1038/s41591-023-02603-1. Epub 2023 Oct 16.
5
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.用于评估resmetirom治疗非酒精性脂肪性肝炎的3期MAESTRO临床项目设计
Aliment Pharmacol Ther. 2024 Jan;59(1):51-63. doi: 10.1111/apt.17734. Epub 2023 Oct 2.
6
Impact of Thyroid Function on the Prevalence and Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease.甲状腺功能对代谢相关脂肪性肝病患病率和死亡率的影响。
J Clin Endocrinol Metab. 2023 Jun 16;108(7):e434-e443. doi: 10.1210/clinem/dgad016.
7
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis.甲状腺激素作为非酒精性脂肪性肝炎的疾病修饰因子和治疗靶点。
Expert Rev Endocrinol Metab. 2022 Sep;17(5):425-434. doi: 10.1080/17446651.2022.2110864. Epub 2022 Aug 11.
8
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.全球非酒精性脂肪性肝病的患病率和发病率：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0. Epub 2022 Jul 5.
9
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.